Claros Diagnostics, Inc.: Series A $7.8M

Claros Diagnostics (Woburn, MA) is developing a handheld disease monitoring device that allows anyone to perform laboratory-quality blood tests in any setting, has closed a $7.8M Series A financing. The round was led by Oxford Bioscience Partners along with, Accelerated Technologies Partners, and Commons Capital.

Ovalis, Inc.: Series B $6.6M

Ovalis (Mountain View, CA) a developer of catheter-based products for repairing cardiac defects, has raised around $6.6 million in Series B funding. Return backers include Abbott Labs, De Novo Ventures and Latterell Venture Partners.

Kolis Scientific, Inc.: Series A $15.1M

Kolis Scientific (Morrisville, NC) is developing an outpatient-based treatment for a common ophthalmic condition, has closed a $15.1M Series A financing led by Quaker BioVentures, De Novo Ventures and Spray Venture Partners.

iBalance Medical, Inc.: Series A $13.5M

iBalance Medical (Boulder, CO) a developer of axial knee realignment systems, has expanded its Series A round to a total of $13.5M. Return backers include Sutter Hill Venture Partners and Skyline Ventures.

EyeGate Pharma, Inc.: Series B $12M

EyeGate Pharma (Waltham, MA) a pharmaceutical company pioneering the use of iontophoresis technology to deliver therapeutics for ocular indications, announced that it has closed on a $2M extension of its Series B, bringing the total of the financing to $12M. This funding comes from the Nexus Group, the round was originally led by Innoven Partenaires and Ventech.

CORRECTION: Symphony Medical, Inc.

Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised $5M, bringing the aggregate investment in all rounds into Symphony Medical to $17 million. The only participants in the round were Domain Associates, Johnson & Johnson Development Corp., Morgenthaler Ventures and Triathlon Medical Ventures.

NovaVision, Inc.: Series C $20M

NovaVision (Boca Raton, FL) a non-invasive device that may restore vision loss in stroke and traumatic brain injury patients has raised $20M in Series C. The deal was led by Chicago Growth Partners and included Johnson & Johnson Development Corp., Oakwood Medical Investors, Tullis-Dickerson, Noro-Moseley Partners, Crossbow Ventures.

Juvaris BioTherapeutics Inc.: Series A $6M

Juvaris BioTherapeutics (Pleasanton, CA) an oncology and anti-infective vaccine platform technology closed on $6M of a $12M Series A led by Kleiner Perkins.

Fluidigm Corporation: Series E $37

Fluidigm Corporation (San Francisco) a producer of integrated fluidic circuits for the life sciences raised $37M in a Series E financing. The round was lead by Cross Creek Capital the private equity affiliate of Wasatch Advisors, Inc.

Pacific Biosciences, Inc.: Series D $50

Pacific Biosciences (Menlo Park, CA) a company focused on DNA gene sequencing, has raised approximately $50M in Series D funding. The financing was led by Maverick Capital and included by return backers Alloy Ventures, Kleiner Perkins and Mohr Davidow Ventures.